Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
26/02/2026 12:23
Feb 26 (Reuters) - Kairos Pharma Ltd KAPA.A: KAIROS PHARMA, LTD. ANNOUNCES SIGNING OF TERM SHEET FOR STRATEGIC ASSET ACQUISITION OF TWO CLINICAL ONCOLOGY ASSETS FROM CELYN THERAPEUTICS KAIROS PHARMA, LTD. ANNOUNCES SIGNING OF TERM SHEET FOR STRATEGIC ASSET ACQUISITION OF TWO CLINICAL ONCOLOGY ASSETS FROM CELYN THERAPEUTICS KAIROS PHARMA LTD - TO BUY RIGHTS TO CL-273 AND CL-741 Source text: ID:nBw1PmZt5a Further company coverage: KAPA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kairos Pharma
See all newsBrief: Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics
Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
Brief: Kairos Pharma Announces Virtual KOL Event To Provide Perspectives On ENV105 Interim Efficacy Results In Advanced Prostate Cancer